[HTML][HTML] Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients …
V Gounant, VM Ferré, G Soussi, C Charpentier… - Journal of Thoracic …, 2022 - Elsevier
Introduction Coronavirus disease 2019 resulted in a 30% mortality rate in patients with
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …
[HTML][HTML] Does very poor performance status systematically preclude single agent anti-PD-1 immunotherapy? A multicenter study of 35 consecutive patients
V Gounant, M Duruisseaux, G Soussi, S Van Hulst… - Cancers, 2021 - mdpi.com
Simple Summary Immunotherapies prolong survival of metastatic non-small-cell lung cancer
patients. However, their efficacy in patients with very poor general condition is unknown. …
patients. However, their efficacy in patients with very poor general condition is unknown. …
Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and …
C Vauchier, J Pluvy, N Theou-Anton, G Soussi, N Poté… - Lung Cancer, 2021 - Elsevier
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a major breakthrough in
lung cancer treatment. For patients with advanced non-small-cell lung cancer (NSCLC) and …
lung cancer treatment. For patients with advanced non-small-cell lung cancer (NSCLC) and …
Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine …
V Gounant, VM Ferré, G Soussi, C Charpentier… - MedRxiv, 2021 - medrxiv.org
Hypothesis Coronavirus disease 2019 (COVID-19) resulted in a 30% mortality rate in thoracic
cancer patients. Given that cancer patients were excluded from serum anti-severe acute …
cancer patients. Given that cancer patients were excluded from serum anti-severe acute …
Epidemiology of lung cancer in France and in the world
S Brosseau, J Pluvy, G Soussi, G Zalcman… - La Revue du …, 2020 - europepmc.org
Epidemiology of lung cancer in france and in the world. Lung cancer is the leading cause of
death from cancer worldwide. In France, lung cancer is the second most common cancer in …
death from cancer worldwide. In France, lung cancer is the second most common cancer in …
[HTML][HTML] Grade 3–4 immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients are correlated with better …
N Guezour, G Soussi, S Brosseau, B Abbar, C Naltet… - Cancers, 2022 - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICIs) recently became a standard treatment
for advanced non-small-cell lung cancers (NSCLCs). Immune-related adverse events (irAEs…
for advanced non-small-cell lung cancers (NSCLCs). Immune-related adverse events (irAEs…
[HTML][HTML] Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor …
C Bouchez, J Pluvy, G Soussi, M Nguenang… - BMC cancer, 2020 - Springer
Background Choroidal metastases are the most common eye metastatic site. The prevalence
of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to 7% in …
of choroidal metastases in NSCLC patients has been reported to vary from 0.2 to 7% in …
[HTML][HTML] Second lung malignancy and Richter syndrome in chronic lymphocytic leukemia: case report and literature review
G Soussi, S Daboussi, S Mhamdi, Z Moatemri… - Multidisciplinary …, 2017 - Springer
Background Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative
disease. Transformation into Richter disease and occurrence of second malignancies …
disease. Transformation into Richter disease and occurrence of second malignancies …
[HTML][HTML] Transthoracic lung biopsy for pulmonary nodules≤ 20 mm in routine clinical care
E Lissavalid, A Khalil, G Soussi, MP Debray… - ERJ Open …, 2022 - Eur Respiratory Soc
Background Computed tomography (CT) screening has improved lung cancer survival, yet
increasingly detects small lung lesions. Thus, the number of transthoracic lung biopsies (TTLB…
increasingly detects small lung lesions. Thus, the number of transthoracic lung biopsies (TTLB…
Development and validation of a prognostic index for survival in non-small cell lung cancer: results from a Tunisian cohort study
G Soussi, NB Alaya, N Chaouch, H Racil - Cancer Epidemiology, 2018 - Elsevier
Introduction Despite the continuous efforts made with the TNM system, the issue of
heterogeneity of prognosis within the stages of non-small cell lung cancer (NSCLC) could not be …
heterogeneity of prognosis within the stages of non-small cell lung cancer (NSCLC) could not be …